Turning Point Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.57 Insider Own0.70% Shs Outstand49.61M Perf Week0.16%
Market Cap3.74B Forward P/E- EPS next Y-7.21 Insider Trans-1.39% Shs Float49.30M Perf Month0.79%
Income-275.50M PEG- EPS next Q-1.69 Inst Own94.79% Short Float6.13% Perf Quarter150.60%
Sales6.10M P/S613.27 EPS this Y-24.70% Inst Trans1.65% Short Ratio1.62 Perf Half Y46.69%
Book/sh17.97 P/B4.18 EPS next Y-3.70% ROA-26.90% Target Price73.43 Perf Year2.51%
Cash/sh18.45 P/C4.07 EPS next 5Y- ROE-28.00% 52W Range23.77 - 82.20 Perf YTD57.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.41% Beta-
Dividend %- Quick Ratio20.40 Sales past 5Y- Gross Margin- 52W Low216.74% ATR1.83
Employees248 Current Ratio20.40 Sales Q/Q-98.40% Oper. Margin- RSI (14)80.57 Volatility0.39% 0.59%
OptionableYes Debt/Eq0.00 EPS Q/Q-106.80% Profit Margin- Rel Volume0.85 Prev Close75.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.86M Price75.29
Recom1.80 SMA200.53% SMA5047.94% SMA20075.31% Volume243,453 Change0.15%
May-20-22Initiated BofA Securities Buy $58
Dec-07-21Initiated Cowen Outperform
Oct-11-21Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-30-21Initiated Stifel Hold $75
Jan-19-21Reiterated H.C. Wainwright Buy $130 → $190
Dec-08-20Initiated JMP Securities Mkt Outperform $125
Sep-21-20Reiterated H.C. Wainwright Buy $88 → $100
Jul-10-20Initiated Oppenheimer Outperform $90
May-26-20Reiterated H.C. Wainwright Buy $72 → $88
Mar-17-20Reiterated H.C. Wainwright Buy $70 → $72
Nov-14-19Initiated ROTH Capital Buy $65
Sep-25-19Initiated H.C. Wainwright Buy $70
Sep-10-19Initiated Wedbush Outperform
Jul-24-19Initiated Guggenheim Buy $58
May-13-19Initiated Wells Fargo Outperform
May-13-19Initiated SVB Leerink Outperform $42
May-13-19Initiated RBC Capital Mkts Outperform $48
May-13-19Initiated Goldman Buy $50
Jun-24-22 09:00AM  
Jun-22-22 05:19PM  
Jun-09-22 10:43AM  
Jun-08-22 01:20PM  
Jun-06-22 01:24PM  
Jun-03-22 04:14PM  
May-26-22 04:30PM  
May-16-22 08:30AM  
May-10-22 04:05PM  
May-09-22 06:50AM  
May-05-22 03:28PM  
Apr-28-22 07:30AM  
Apr-12-22 04:46PM  
Mar-29-22 09:00AM  
Mar-21-22 08:00AM  
Mar-09-22 04:05PM  
Mar-07-22 05:00PM  
Mar-01-22 04:05PM  
Feb-28-22 04:02PM  
Feb-04-22 01:17PM  
Feb-02-22 01:38PM  
Jan-25-22 12:00PM  
Jan-20-22 09:00AM  
Jan-18-22 09:00AM  
Jan-12-22 11:37AM  
Dec-21-21 06:38PM  
Dec-20-21 08:00AM  
Dec-16-21 09:38AM  
Nov-30-21 09:13AM  
Nov-10-21 04:01PM  
Nov-09-21 04:01PM  
Nov-08-21 04:01PM  
Nov-02-21 04:01PM  
Oct-23-21 09:12AM  
Oct-18-21 05:27AM  
Oct-13-21 04:01PM  
Oct-11-21 04:05PM  
Oct-08-21 01:11PM  
Oct-07-21 07:00AM  
Oct-04-21 09:00AM  
Oct-01-21 12:44PM  
Sep-30-21 04:30PM  
Sep-22-21 12:02PM  
Sep-08-21 04:05PM  
Sep-01-21 09:00AM  
Aug-16-21 09:00AM  
Aug-11-21 04:01PM  
Aug-09-21 04:02PM  
Jul-28-21 04:15PM  
Jul-07-21 07:17AM  
Jul-06-21 11:04AM  
Jun-29-21 09:00AM  
Jun-17-21 08:30AM  
Jun-01-21 09:00AM  
May-25-21 09:00AM  
May-17-21 09:00AM  
May-08-21 04:34AM  
May-05-21 04:05PM  
Apr-26-21 09:00AM  
Apr-23-21 12:28PM  
Apr-12-21 09:00AM  
Apr-09-21 09:00AM  
Apr-06-21 08:04AM  
Apr-05-21 04:01PM  
Mar-31-21 04:05PM  
Mar-23-21 06:08AM  
Mar-10-21 06:08PM  
Mar-04-21 09:00AM  
Mar-01-21 04:02PM  
Feb-23-21 10:59AM  
Feb-18-21 09:00AM  
Feb-12-21 09:32AM  
Feb-04-21 08:30AM  
Jan-29-21 08:30AM  
Jan-21-21 11:50PM  
Jan-13-21 04:45AM  
Jan-11-21 07:40AM  
Dec-08-20 09:36AM  
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naive and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reich SiegfriedEVP & Chief Scientific OfficerFeb 09Sale36.3039714,4113,448Feb 11 06:10 PM
North AnnetteEVP & General CounselFeb 09Sale36.3066924,28511,696Feb 11 06:09 PM
Partridge Andrew JohnEVP & Chief Commercial OfficerFeb 09Sale36.302218,02222,078Feb 11 06:09 PM
Countouriotis AthenaPresident & CEOFeb 09Sale36.302,971107,84747,930Feb 11 06:07 PM
Hirmand MohammadEVP & Chief Medical OfficerFeb 09Sale36.3066924,2856,838Feb 11 06:08 PM
North AnnetteEVP, General Counsel & Secty.Aug 30Option Exercise17.0010,000170,00022,365Aug 31 05:26 PM
North AnnetteEVP, General Counsel & Secty.Aug 30Sale80.0010,000800,00012,365Aug 31 05:26 PM
Partridge Andrew JohnEVP & Chief Commercial OfficerJul 14Sale74.901,869139,98821,767Jul 15 05:53 PM